Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | ANPEP | P15144 | 2/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | LAP3 | P28838 | 3/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | MME | P08473 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6898138 | 1.00 | CYP3A4 (0.46) | CYP3A4MAPK1LMNAPKMALDH1A1 | |
| SCHEMBL7684657 | 0.88 | MME (0.38) | CYP3A4MAPK1LMNAPKMALDH1A1 | |
| SCHEMBL6897256 | 0.88 | MME (0.38) | CYP3A4MAPK1LMNAPKMALDH1A1 | |
| SCHEMBL6895501 | 0.88 | CTSB (0.45) | LMNAPKMCTSB | |
| SCHEMBL6895506 | 0.88 | CTSB (0.45) | LMNAPKMCTSB | |
| SCHEMBL6897114 | 0.88 | MME (0.38) | CYP3A4MAPK1LMNAPKMALDH1A1 | |
| SCHEMBL27479232 | 0.86 | MAPK1 (0.52) | CYP3A4MAPK1CTSBKMT2AMME | |
| SCHEMBL6732315 | 0.86 | MAPK1 (0.52) | CYP3A4MAPK1CTSBKMT2AMME | |
| SCHEMBL6735719 | 0.80 | MME (0.49) | CYP3A4MAPK1MME | |
| SCHEMBL6740816 | 0.78 | ATM (0.46) | CYP3A4MAPK1CTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730784-B2 | AS THERAPEUTIC AGENTS FOR AUTOIMMUNE DISEASES SUCH AS RHEUMATOID ARTHRITIS | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2004-05-04 | — | — | US | disclosed |
| US-20020198376-A1 | Novel urea derivatives | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-26 | — | — | US | disclosed |
| US-6492370-B1 | Urea derivatives and pharmaceutical compositions thereof | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2002-12-10 | — | — | US | disclosed |
| EP-1072591-A1 | NOVEL UREA DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198376-A1 | Novel urea derivatives | TNF, CTH, CFH | CYP3A4 1139/4885MAPK1 2297/4885LMNA 4204/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.